Business
Assertio Reports Fourth Quarter and Full Year 2025 Financial Results
LAKE FOREST, Ill, March 16, 2026--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results for the fourth quarter and full year ended December 31, 2025.
About this update from Assertio Holdings, Inc.
[{"type":"text","content":"Delivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance","length":68,"tagName":"p","attribs":{}},{"type":"text","content":"Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M in FY2026","length":93,"tagName":"p","attribs":{}},{"type":"text","content":"LAKE FOREST, Ill, March 16, 2026--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results for the fourth quarter and full year ended December 31, 2025.","length":373,"tagName":"p"},{"type":"text","content":"Mark Reisenauer, Chief Executive Officer, stated: "Our core asset, Rolvedon, continues to represent a meaningful revenue opportunity, as reflected in both our 2025 results and 2026 outlook, and our strong commercial infrastructure and market access capabilities provide a platform to expand and build an oncology portfolio in a disciplined way.","length":349,"tagName":"p"},{"type":"text","content":"Since taking over as CEO, I’ve taken a close look at our business to understand where we have a real advantage and where we need to stay disciplined. That has reinforced our focus on finding products that leverage our existing capabilities rather than pursuing on-market specialty product acquisitions, which we do not view as a sustainable path for long-term growth. Our priorities are clear: leverage our core strengths, allocate capital thoughtfully, and build a differentiated oncology franchise that drives durable shareholder value."","length":544,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 Financial Highlights","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Rolvedon net product sales were $0.4 million for the fourth quarter of 2025, down from $15.4 million in the prior-year quarter. The expected decline in sales was driven by the sell-in, executed in the third quarter of 2025, which covered the next two quarters of demand to ensure uninterrupted patient supply of Rolvedon as product was transitioned to a new distribution partner and operations were consolidated under a single commercial entity. Rolvedon continues to be a leader in market share in the Medicare ...